Welcome to MBT

MicroBiome Therapeutics™ is developing pharmaceutical products that improve health status by interacting with the human microbiome in specific ways.  We are a leader in the development of evidence-based microbiome modulators–products designed to alter bacterial populations and their environment in the gastrointestinal (GI) tract to prevent or treat serious health conditions.

read more

About Microbiome Modulators

MBT’s microbiome modulators are based on the growing understanding that the composition of the large populations of bacteria and other microorganisms (collectively referred to as the microbiota) resident in the human GI tract can have a significant impact on health. Microbiome modulators shift the GI microbiota and their environment in specific ways to achieve improved health outcomes.

read more

Company Updates

May 12, 2015 Press Release. MicroBiome Therapeutics Receives Positive Response From FDA For Use Of Expedited Regulatory Pathway For Diabetes Drug NM505.

April 7, 2015 Press Release.  MicroBiome Therapeutics Reports Advances In Three Microbiome Modulator Programs As It Launches Series B Financing.

February 9, 2015 Press Release.  MicroBiome Therapeutics Receives Notice Of Allowance For U.S. Patent Covering Glyceollin As A Treatment For Diabetes And Obesity.